Tharimmune.

Nov 30, 2023 · View THAR: Tharimmune, Inc.investment & stock information. Get the latest THAR: Tharimmune, Inc. detailed stock quotes, stock data, Real-Time ECN, charts, stats and ... Tharimmune shares opened at $2.93, later reaching a high of $4.79. The stock recently sold for $4.20, up 46%, at around 10:10 a.m. ET. Earlier Monday, Tharimmune said that a Phase 1 study for ...Tharimmune, Inc.THAR announced data from an early-stage study on TH104 and the development timeline for a phase IIa study in chronic pruritis in primary biliary cholangitis (“PBC”) patients.How much is Tharimmune stock worth today? ( NASDAQ: THAR) Tharimmune currently has 17,511,839 outstanding shares. With Tharimmune stock trading at $0.21 per share, the total value of Tharimmune stock (market capitalization) is $3.68M. Tharimmune stock was originally listed at a price of $3.48 in Jan 12, 2022.

Tharimmune, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers. It also develops the Trident Artificial Intelligence (TAI) precision medicine platform which is used to identify ...Definition of heteroimmune in the Definitions.net dictionary. Meaning of heteroimmune. What does heteroimmune mean? Information and translations of heteroimmune in the …

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or “uncontrollable itching” in PBC, a rare and orphan ...

Tharimmune, Inc.(NasdaqCM:THAR) dropped from NASDAQ Composite Index Sep. 22: CI Top Midday Decliners Sep. 11: MT Hillstream BioPharma Obtains Exclusive Option to Acquire Clinical Stage Asset for Itchy Skin Sep. 11: MT Hillstream BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months …Tharimmune has granted the underwriters a 45-day option to purchase up to an additional 1,500,000 shares of common stock and/or Pre-Funded Warrants to cover over-allotments at the public offering ...03/16/2023. 12/31/2022. 10-K. Annual Reports. SEC Filings provided by EDGAR Online, Inc. Prev Page Next Page. Tharimmune Inc. SEC filings breakout by MarketWatch. View the THAR U.S. Securities and ...Tharimmune, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting ...

Get the latest Tharimmune Inc (THAR) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

Nov 27, 2023 · Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The …Nov 27, 2023 · Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan ... Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and …Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a ...Tharimmune says the main purpose of its reverse stock split is increasing the price of THAT shares. The company is doing this to get its shares above the $1 minimum bid price needed to remain on ...Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...7 days ago ... Tharimmune also announced plans on a development timeline for a Phase 2a study in chronic pruritis in primary biliary cholangitis (PBC) patients ...

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On November 17, 2023, Tharimmune, Inc. (the “Company”) filed a Certificate of Amendment (the “Amendment”) to its Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware pursuant to which it effected a 1-for-25 …About Tharimmune, Inc. Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases.Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...Tharimmune, Inc. ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic ...Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023 BRIDGEWATER, NJ / ACCESSWIRE / September 22, 2023 / Hillstream BioPharma Inc. , (NASDAQ:HILS), a biotechnology company developing innovative therapeutic candidates in rare immune, inflammatory and oncologic diseases …Tharimmune (NASDAQ: THAR) stock is taking off on Tuesday after the company underwent a name change. A filing with the Securities and Exchange …

TeraImmune, Inc. is a biotechnology company that develops innovative immune-cell therapies. Our investigational technology programs regulatory T (Treg) cells to recognize …

Tharimmune says the main purpose of its reverse stock split is increasing the price of THAT shares. The company is doing this to get its shares above the $1 minimum bid price needed to remain on ...17-Nov-2023 ... Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and ...That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares ...US4327052001. Tharimmune, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers. It also develops the Trident Artificial Intelligence (TAI) precision medicine platform which is ...Tharimmune Inc (NASDAQ:THAR)’s traded shares stood at 69929.0 during the last session, with the company’s beta value hitting 2.78. At the close of trading, the stock’s price was $3.02, to imply a decrease of -15.88% or -$0.57 in intraday trading. The THAR share’s 52-week high remains $66.25, putting it -2093.71% down since that peak …Nov 27, 2023 · Tharimmune shares opened at $2.93, later reaching a high of $4.79. The stock recently sold for $4.20, up 46%, at around 10:10 a.m. ET. Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan ...

View the latest Tharimmune Inc. (THAR) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Tharimmune, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for ...

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases ...About Tharimmune, Inc. Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases.Discover historical prices for THAR stock on Yahoo Finance. View daily, weekly or monthly format back to when Tharimmune, Inc. stock was issued. About Tharimmune. Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and ...17-Nov-2023 ... Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and ...Nov 28, 2023 · That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares ... Hillstream BioPharma Inc is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism ...TH104 is a product which has been developed by embedding drug onto a proprietary transmucosal buccal film which adheres to the inside of the mouth. TH104 has key features which we believe make it an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. The active molecule, nalmefene, has a dual ... Nov 28, 2023 · That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares ... Nov 6, 2023 · Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ... 17-Nov-2023 ... Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and ...Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Hillstream BioPharma, Inc. Stock Symbol NASDAQ:THAR. Company Type For Profit. Contact Email [email protected]. Phone Number +1 302.743.2995. Hillstream BioPharma is a development-stage company advancing improved therapies for patients with cancer via …

Tharimmune, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for ...That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares ...Hillstream BioPharma Inc is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism ...Tharimmune Inc THAR has executed an exclusive worldwide licensing agreement with Avior Inc. to develop, market, and commercialize a clinical-stage asset, AV104 (to be renamed TH104). TH104 has a ...Instagram:https://instagram. nyse bx financialsstock solar energybest automated futures trading systembest bank stocks Small Cary firm inks potential $24M deal with public company. Tharimmune is licensing the assets of a small pharmaceutical company in Cary. Klimenko Aleksandr. By Zac Ezzone – Staff writer ...Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ... lithium stock companiesbac market watch Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or “uncontrollable itching” in PBC, a rare and orphan ... stock tmf Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan ...Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and …Chg %. $2.8750. -0.1450. -4.80%. Tharimmune Inc. advanced stock charts by MarketWatch. View THAR historial stock data and compare to other stocks and exchanges.